AACR 2024 | An epitope editing approach to enable the use of targeted immunotherapy in AML
Gabriele Casirati, MD, PhD, Boston Children’s Hospital/Dana Farber Cancer Institute, Boston, MA, provides details on a promising strategy with the potential to advance targeted immunotherapy for acute myeloid leukemia (AML). Novel immunotherapeutic approaches are highly efficacious across most hematological malignancies; however, their application to AML is restricted due to a lack of leukemia-specific targets on AML blasts. Antigens on the surface of blasts are shared with progenitor and mature myeloid cells, leading to on-target/off-tumor toxicity. Dr Casirati presents an approach that uses epitope-engineering of donor stem cells, which allows for more specific gene modifications and enables safer outcomes and reduced toxicity. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
